US-based biopharma VentiRx Pharmaceuticals has appointed Dr James Kyle Bryan as chief medical officer.
Dr Bryan joins from Seattle Genetics, where he served as VP, medical affairs and before that as VP of global product development.
During his career, Dr Bryan has focused on drug discovery in oncology, and has a medical background in haematology and oncology.
This experience will benefit VentiRx as it prepares to advance the development of VTX-2337 for patients with ovarian cancer and head and neck cancer.
“His extensive experience in oncology drug development combined with his strong connections to oncology thought leaders will be invaluable to VentiRx going forward,” said Dr Robert Hershberg, CEO of VentiRx. “We are delighted to have him join the VentiRx team.”